Table 6.

Risk factor comparison of 230 diffuse tenosynovial giant cell tumor (TGCT) of lower extremities.

Risk factors		Worst pain VASa score, 0 best score and 10 worst score		Worst stiffness VAS score, 0 best score and 10 worst score		PROMIS-PFb T score, mean 50 (SD 10), MIDc 4.0-6.0		SF-12d, PCSe score, mean 50 (SD 10), MID >3.29		SF-12, MCSf score, mean 50 (SD 10), MID >3.77		EQ-5D-5L DSg utility score, 0 death and 1 full health, MID .037-.069
		Score	P value	Score	P value	Score	P value	Score	P value	Score	P value	Score	P value
Gender
	Male (n=51)	3.63	.70	4.13	.71	42.2	.23	39.9	.11	49.0	.04	.75	.17
	Female (n=179)	3.84		3.98		41.0		37.5		45.6		.71
Age of diagnosis
	<35 years (n=119)	3.70	.58	3.74	.09	42.1	.07	39.2	.07	46.9	.38	.73	.22
	≥35 years (n=109)	3.89		4.32		40.4		36.8		45.6		.71
TGCT localization
	Knee (n=170)	3.78	.93	3.92	.07	41.6	.29	38.1	.99	46.3	.98	.73	.40
	Hip, ankle, foot, other (n=60)	3.82		4.55		40.5		38.1		46.3		.71
Initial surgery
	Arthroscopy (n=113)	3.93	.82	4.19	.64	41.6	.66	38.3	.86	45.6	.64	.73	.25
	Open surgeryh (n=190)	3.84		4.01		41.2		38.0		46.4		.70
Recurrence
	Yes (n=146)	4.23	<.001	4.55	<.001	40.5	.02	37.7	.49	45.1	.04	.70	.02
	No (n=84)	3.04		3.08		42.7		38.7		48.2		.75
Total no. of surgeries
	1 surgery (n=86)	3.79	.69	3.74	.09	42.0	.20	38.7	.48	46.1	.89	.73	.44
	≥2 surgeries (n=124)	3.94		4.38		40.8		37.7		46.3		.71
Last treatment for TGCT
	≤1 year (n=72)	4.10	.37	4.35	.37	40.4	.17	35.4	.01	45.6	.59	.70	.17
	>1 year ago (n=138)	3.76		4.00		41.8		39.5		46.5		.73

^aVAS: Visual Analog Scale.

^bPROMIS-PF: Patient-Reported Outcomes Measurement Information System-Physical Function.

^cMID: minimal important difference represents the smallest difference or change beyond statistical significance in an outcome measure score that would be considered important by the value patients place on change ref [18-20].

^dSF: Short-Form.

^ePCS: physical component summary.

^fMCS: mental component summary.

^gDS: descriptive system.

^hOne- or two staged open synovectomy.